- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02827721
Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)
March 23, 2020 updated by: Dr. Frederik Trinkmann, Universitätsmedizin Mannheim
Current guideline-based criteria defining COPD do not meet the challenges set by the complex pathophysiology of the disease.
The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and therapeutic monitoring of COPD.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mannheim, Germany, 68167
- Recruiting
- University Medical Center Mannheim
-
Principal Investigator:
- Saur Joachim, Prof. Dr.
-
Principal Investigator:
- Henzler Thomas, Prof. Dr.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
patients with indication for routine lung function testing
Description
Inclusion Criteria:
- known or suspected COPD
- known or suspected obstructive ventilation disorder
- pulmonary healthy controls
Exclusion Criteria:
- pregnancy
- inability to participate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
pulmonary healthy controls
Patients without known or suspected pulmonary disease
|
|
COPD
Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
lung clearance index (LCI) as determined by multiple breath washout
Time Frame: 30 minutes
|
30 minutes
|
airway resistance and reactance (R5, X5, R-D5-20) as determined by impulse oscillometry
Time Frame: 30 minutes
|
30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
repeatability of lung clearance index (LCI)
Time Frame: 30 minutes
|
30 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (ANTICIPATED)
November 1, 2020
Study Completion (ANTICIPATED)
November 1, 2020
Study Registration Dates
First Submitted
June 30, 2016
First Submitted That Met QC Criteria
July 5, 2016
First Posted (ESTIMATE)
July 11, 2016
Study Record Updates
Last Update Posted (ACTUAL)
March 24, 2020
Last Update Submitted That Met QC Criteria
March 23, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MBW-COPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Emphysema
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy
-
Beijing Municipal Science & Technology CommissionUnknownCombined Pulmonary Fibrosis and EmphysemaChina
-
Asan Medical CenterUnknownPulmonary Disease, Chronic Obstructive | Microbiota | Emphysema or COPDKorea, Republic of
-
Aarhus University HospitalRecruitingChronic Obstructive Pulmonary Disease | Emphysema or COPDDenmark
-
IHF GmbH - Institut für HerzinfarktforschungNot yet recruitingEmphysema or Chronic Obstructive Pulmonary DiseaseGermany
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
Hospices Civils de LyonUnknownEmphysema | Pulmonary Fibrosis | Healthy Subjects | Combined Pulmonary Fibrosis and Emphysema SyndromeFrance
Clinical Trials on impulse oscillometry
-
University Hospital, ToursCompletedIdiopathic Pulmonary FibrosisFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingAsthma | Small Airway DiseaseItaly
-
Universitätsmedizin MannheimCompletedPulmonary Hypertension
-
Universitätsmedizin MannheimUnknownIdiopathic Pulmonary Fibrosis | Interstitial Lung Disease | Sarcoidosis | Pulmonary Healthy Controls | Non-specific Interstitial Pneumonia | Granulomatosis With Polyangiitis (Wegener's Disease)Germany
-
Universitätsmedizin MannheimCompletedPulmonary Healthy Controls | Bronchial Asthma
-
Universitätsmedizin MannheimUnknownChronic Obstructive Pulmonary Disease | Interstitial Lung Disease | Bronchial AsthmaGermany
-
University of RochesterCompletedLung Function Decreased | Breathing, MouthUnited States
-
University of RochesterRecruitingAsthma | Vocal Cord Dysfunction | Lung Function Decreased | Breathing, Mouth | Laryngeal ObstructionUnited States
-
Shengjing HospitalRecruitingAsthma | Diagnoses Disease | COPD | Asthma-COPD Overlap SyndromeChina
-
Scius Healthcare Solutions Pty LtdChiesi AustraliaNot yet recruitingChronic Obstructive Pulmonary Disease | Asthma